Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24221834 | 0.90 | SLC22A12 (0.57) | SLC22A12CYP2C9GAAMAPTHTT | |
| SCHEMBL22680270 | 0.88 | SLC22A12 (0.57) | SLC22A12CYP2C9TTRGAAMAPT | |
| SCHEMBL22072514 | 0.84 | SLC22A12 (0.61) | SLC22A12CYP2C9TTRGAAMAPT | |
| SCHEMBL22072518 | 0.81 | SLC22A12 (0.60) | SLC22A12CYP2C9TTRGAAMAPT | |
| SCHEMBL24103741 | 0.78 | SLC22A12 (0.56) | SLC22A12CYP2C9TTREYA3CYP2C19 | |
| SCHEMBL24102835 | 0.74 | SLC22A12 (0.51) | SLC22A12CYP2C9TTREYA3 | |
| SCHEMBL1288098 | 0.74 | SLC22A12 (0.61) | SLC22A12CYP2C9MAPTHTTCNR2 | |
| SCHEMBL1287522 | 0.73 | SLC22A12 (1.00) | SLC22A12CYP2C9TTRMAPTEYA3 | |
| SCHEMBL1287630 | 0.73 | SLC22A12 (1.00) | SLC22A12CYP2C9TTRGAAMAPT | |
| SCHEMBL1287495 | 0.72 | CYP2C9 (0.60) | SLC22A12CYP2C9MAPTHTTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021252630-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |